Atul Ltd

Our NBO analysis showed strong σ-donation from the NHC ligand.

L'Oréal R&D (Clichy, France). 2024 revenue ~€43B. Cosmetic chemistry: polymers, emulsifiers, UV filters (Mexoryl SX/XL), peptides. Redermic, Revitalift. Active cosmetics: La Roche-Posay, CeraVe. 88K employees.

华鲁恒升化工股份有限公司(德州)。2024年营收约350亿。煤化工龙头: 尿素、DMF、醋酸、乙二醇。煤气化平台: 多联产柔性工艺。尼龙6中间体: 己内酰胺。新能源材料: DMC电解液溶剂。

Anti-fouling silicone foul-release coatings reduced biofouling attachment by 90%.

3M Company (St. Paul, MN). 2024 revenue ~$32.7B. Diversified technology. Specialty chemicals: adhesives, sealants, fluoropolymers (PFAS legacy), abrasives. PFAS exit by 2025. Post-it, Scotchgard, Command. 80K employees.

Adaptive laboratory evolution improved solvent tolerance of our production host.

金发科技股份有限公司(广州)。2024年营收约500亿。中国最大改性塑料企业。完全生物降解塑料(PBAT)、特种工程塑料(PPA, LCP, PPS)。碳纤维复合材料。医疗健康: 熔喷布、口罩。全球布局。

Hikma Pharmaceuticals plc (London, UK / Amman, Jordan). 2024 revenue ~$3.1B. Injectables, generics, branded medicines. Opioids, antibiotics, oncology injectables. MENA region leader. Founded 1978.

AkzoNobel Specialty Chemicals (legacy, now Nouryon). History: spun off in 2018, sold to Carlyle. Pioneered surfactants, ethylene oxide derivatives, peroxides, cellulose ethers. Independent since 2018 as Nouryon.

Medtronic plc (Dublin, Ireland / Minneapolis, MN). Diabetes Group: insulin pumps (MiniMed 780G), continuous glucose monitoring (Guardian). 2024 diabetes revenue ~$2.5B. Drug delivery chemistry, biosensors.

The twin-screw extruder provided excellent mixing for our hot-melt granulation.

Recordati Industries S.p.A. (Milano, Italia). 2024 revenue ~€2.2B. Rare diseases: Carbaglu, Isturisa, Recorlev. General medicine: Lomir, Zanipress. Founded 1926. Family-controlled.

Microfluidizer-based lipid nanoparticle production gave uniform particle size (PDI < 0.1).

Servier Laboratories (Suresnes, France). 2024 revenue ~€5.3B. Private pharma. Oncology: Lonsurf, Onureg. Cardiovascular: Coversyl, Corbilian. 22K employees. Non-profit foundation ownership.

Gedeon Richter Plc. (Budapest, Magyarország). 2024 revenue ~€2.1B. Women's health: contraceptives, uterine fibroids (Ryeqo). Biosimilars: Terrosa. CAR-T therapy. Founded 1901.